PCM
NVAX icon

Prelude Capital Management’s Novavax NVAX Stock Holding History

Prelude Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,100
Closed -$1.16M – 2100
2021
Q4 		$1.16M Hold
8,100
– – 0.03% 539
2021
Q3 		$1.68M Buy
8,100
+400
+5% +$88.2K 0.04% 371
2021
Q2 		$1.64M Hold
7,700
– – 0.05% 377
2021
Q1 		$1.4M Buy
7,700
+3,100
+67% +$618K 0.04% 474
2020
Q4 		$513K Buy
+4,600
New +$489K 0.01% 714
2016
Q3 		– Sell
-245
Closed -$36K – 1743
2016
Q2 		$36K Buy
+245
New +$28.1K 0.01% 1113

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Prelude Capital Management's NVAX Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Novavax (NVAX) in Q2 2026: 20,300 shares worth $191K. The stake represents 0.01% of the portfolio and ranks #997 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in NVAX as recently as Q1 2025.

Prelude Capital Management first reported a position in NVAX in Q3 2015 and has held it in 4 quarters since. 267 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Prelude Capital Management held 20,300 shares of Novavax worth $191K as of Q2 2026.
  • Novavax was a new Prelude Capital Management position in Q2 2026.
  • Novavax made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #997 holding.
  • Prelude Capital Management first reported a position in Novavax in Q3 2015 and has held it in 4 quarters since.
  • 267 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.